Showing results (61-70 of 76) with videos related to

Sort By:
Pageof 8
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisoneNathalie A Johnson, Graham W Slack, Kerry J Savage, et al.
Blood|July 28, 2005
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival predictionSilvia Bea, Andreas Zettl, George Wright, et al.
Nature|December 24, 2010
Oncogenically active MYD88 mutations in human lymphomaVu N Ngo, Ryan M Young, Roland Schmitz, et al.
The Journal of Experimental Medicine|September 17, 2003
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphomaAndreas Rosenwald, George Wright, Karen Leroy, et al.
The New England Journal of Medicine|June 20, 2024
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell LymphomaChristopher Melani, Rahul Lakhotia, Stefania Pittaluga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2022
Gene Expression Signatures for the Accurate Diagnosis of Peripheral T-Cell Lymphoma Entities in the Routine Clinical PracticeCatalina Amador, Alyssa Bouska, George Wright, et al.
Medrxiv : the Preprint Server for Health Sciences|March 31, 2025
High-grade B-cell lymphoma, not otherwise specified: an LLMPP studyBrett Collinge, Laura K Hilton, Jasper Wong, et al.
Blood|March 18, 2014
Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphomaJaveed Iqbal, George Wright, Chao Wang, et al.
Blood|May 3, 2024
Motive and opportunity: MYC rearrangements in high-grade B-cell lymphoma with MYC and BCL2 rearrangements (an LLMPP study)Laura K Hilton, Brett Collinge, Susana Ben-Neriah, et al.
Cancer Cell|March 7, 2003
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphomaAndreas Rosenwald, George Wright, Adrian Wiestner, et al.
Pageof 8